Sun Pharma Advanced Research shares tank 20% after psoriasis drug fails Phase 2 trials

June 4, 2025

Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase 2 trials for psoriasis and atopic dermatitis. The company has decided to discontinue development of the drug. Separately, a surprise FDA inspection is underway at Sun Pharma’s Halol manufacturing facility.

More To Explore

Crude at $120 poses multi-channel risk, but demand still resilient: Aurodeep Nandi

Rising Brent crude prices and a weakening rupee are raising concerns for India’s economy. Policy interventions, including controlled fuel prices and tax reductions, are currently

April 30, 2026

Rate cuts unlikely in near term as inflation stays sticky: Richard Harris

Global market expert Richard Harris anticipates minimal changes to U.S. monetary policy, emphasizing the Fed’s independence. He notes that Big Tech’s recent profitability stems more

April 30, 2026

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.

The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003